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Available online 6 March 2017Background: Lung cancer is the leading cause of cancer-relatedmortality in bothmen andwomen throughout the
world. The need to detect lung cancer at an early, potentially curable stage, is essential andmay reducemortality
by 20%. The aim of this studywas to identify distinct proteomic profiles in bronchoalveolar fluid (BALF) and plas-
ma that are able to discriminate individuals with benign disease from those with non-small cell lung cancer
(NSCLC).
Methods:Using label-freemass spectrometry analysis of BALFduring discovery-phase analysis, a significant num-
ber of proteins were found to have different abundance levels when comparing control to adenocarcinoma (AD)
or squamous cell lung carcinoma (SqCC). Validation of candidate biomarkers identified in BALFwas performed in
a larger cohort of plasma samples by detection with enzyme-linked immunoassay.
Results: Four proteins (Cystatin-C, TIMP-1, Lipocalin-2 and HSP70/HSPA1A) were selected as a representative
group from discovery phase mass spectrometry BALF analysis. Plasma levels of TIMP-1, Lipocalin-2 and
Cystatin-C were found to be significantly elevated in AD and SqCC compared to control.
Conclusion: The results presented in this study indicate that BALF is an important proximal biofluid for the discov-
ery and identification of candidate lung cancer biomarkers.
General significance: There is good correlation between the trend of protein abundance levels in BALF and that of
plasma which validates this approach to develop a blood biomarker to aid lung cancer diagnosis, particularly in
the era of lung cancer screening. The protein signatures identified also provide insight into the molecular mech-
anisms associated with lung malignancy.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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ELISA1. Introduction
Lung cancer is the most common cancer worldwide, in 2012 it con-
tributed to 13% of the total number of new cases diagnosed and is the
most common cause of cancer-related mortality, accounting for more
than 1.4 million deaths per year globally [1]. The overall prognosis re-
mains poor with just over one in eight lung cancer patients living for
five-years or more after their diagnosis. Approximately 85% to 90% of
patients with lung cancer have had direct exposure to tobacco [2,3],
other risk factors include environmental smoke exposure and occupa-
tional exposure to agents such as asbestos [4].. This is an open access article underLung cancer is categorised into two groups, small cell (SCLC) and
non-small cell (NSCLC). The majority of cases are NSCLC (85%) of
which 40% are adenocarcinoma (AD), 25–30% squamous cell carcinoma
(SqCC), 10–15% large cell carcinoma (LCC), and then rarer variants such
as mixed/undifferentiated pulmonary carcinomas [5]. Substantial prog-
ress has beenmade in our understanding of the biological processes and
mutations that cause lung cancer, this has led to the development of
targeted therapy for lung cancer with some marked improvement in
survival in selected groups. Advances in stereotactic radiotherapy for
early stage disease are also a promising new treatment modality for
thosewho are unfit for surgery, which has demonstrated excellent con-
trol of local disease [6–8]. Despite this array of new targeted treatments,
cure remains elusive for the vast majority of patients diagnosed with
lung cancer [9].
Approximately 85% of patients with lung cancer are symptomatic at
presentation, the remainder are detected by interpreting chest radio-
graphs performed for an unrelated health issue [10]. Computedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient data.
BALF Plasma
Control (benign & sarcoid) Control (benign & sarcoid)
n = 16 n = 26
Average age = 56 Average age = 49
8 male/8 female 18 male/8 female
NSCLC NSCLC
n = 26 n = 46
Average age = 65 Average age = 67
13 male/13 female 23 male/23 female
Adenocarcinoma, n = 13 Adenocarcinoma, n = 28
7 stage I/II; 6 stage III/IV 14 stage I/II; 14 stage III/IV
Squamous cell carcinoma, n = 13 Squamous cell carcinoma, n = 18
8 stage I/II; 5 stage III/IV 7 stage I/II; 11 stage III/IV
Patient data table including number of samples, average age, male/female and disease
staging for controls and lung cancer (adenocarcinoma and squamous cell carcinoma).
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smokers, is helping to detect thedisease in its early,more-curable stages
[11]. Screening of asymptomatic individuals has been shown to de-
crease mortality by 20% in those aged 55–74 years who are current
smokers or quit within the last 15 years [12]. Lung cancer screening
has now been endorsed by a number of different medical societies and
is available to many in the United States [13–15]. However concerns re-
main in relation to the high false-positive rate of screening, unnecessary
interventions, and its overall cost effectiveness despite being imple-
mented [16]. Efforts to further risk stratify patients clinically beyond
those criteria employed in the National Lung Cancer Screening, along
with technological developments in lung nodule volumemeasurement,
may ultimately reduce the number and frequency of low dose CT scans
required for population screening [17,18]. Developing a lung cancer bio-
marker to complement radiological imaging is a strategy that may re-
duce false-positive and false-negative screening rates, improve cost-
effectiveness, and aid the earlier detection of this disease [19].
Biomarkers circulating in blood could constitute the gold standard
for non-invasive cancer diagnostics [20]. Blood is the ideal final test me-
dium, however due to the high dynamic range, identification of candi-
date protein biomarkers remains difficult. This high dynamic range,
spanning 10–12 orders of magnitude, is a result of abundant proteins,
such as albumin, representing more than 99% of the total bulk mass of
protein content [21]. Fractionation techniques, such as
immunodepletion, can reduce this dynamic range, however biomarker
discovery in blood remains a challenge [22,23].
One approach to overcome this problem is to analysemore proximal
biofluids such as saliva, urine, exhaled breath condensate and broncho-
alveolar lavage fluid (BALF) [24–28]. Proximal biofluids have amuch re-
duced dynamic range of protein abundances and in some cases are in
direct contactwith the site of the disease [29]. BALF is routinely sampled
during bronchoscopy in individuals with suspected lung cancer, it con-
tains a wide variety of cellular material such as macrophages and neu-
trophils, a large number of proteins produced by epithelial and
inflammatory cells, and tumour cells if present [30].
In the present study, our aim was to identify altered levels of candi-
date protein biomarkers in BALF samples from individuals with lung
cancer compared to a control group diagnosed with benign nodules or
sarcoidosis. Using quantitative mass spectrometry, we identified signif-
icantly changed proteins and catalogued their biological processes and
molecular functions. With this information, a number of candidate bio-
markers were selected for verification and initial validation in blood
samples from lung cancer and control groups. This study may enhance
our knowledge of the proteomic profile induced in the lung microenvi-
ronment by the presence of tumour cells, and may help elucidate the
protein signature created by the tumour cells themselves. Furthermore,
this data may facilitate the identification of a useful clinical biomarker
panel for the diagnosis and monitoring of lung cancer in the future.
2. Material and methods
2.1. Patient information and sample collection
Patient samples were collected according to standard phlebotomy
procedures following informed consent. Institutional ethical approval
was granted from the Beaumont Hospital, Ethics Committee (REC refer-
ence: 10/61). BALF and blood sampleswere collected frompatientswho
were undergoing diagnostic bronchoscopy in Beaumont Hospital, Dub-
lin, Ireland. All samples were immediately placed on ice prior to pro-
cessing and stored at −80 °C until analysis. In total, 42 BALF and 72
plasma samples were analysed (Table 1). After being extracted from
the respiratory airways, the majority of BALF samples appeared to be
clear and any samples with a slightly reddish appearance due to blood
contamination were excluded. Post centrifugation, any BALF samples
forming a distinct layer of red blood cells were excluded. Post mass
spectrometry analysis, all samples were searched individually toidentify associated proteins. Any samples presenting with a large num-
ber of blood based proteins as the top hits during protein identification
(with a similar profile to digested serum/plasma samples) were also ex-
cluded from the main analysis.2.2. Mass spectrometry
To remove debris and cells, BALF samples were centrifuged at
4000 ×g for 15 min at 4 °C. Proteins from the resulting supernatants
were concentrated using 5 kDa Amicons (Millipore) by centrifugation
at 4000×g for 45min at 4 °C. 200 μl of the resulting retenatewas treated
using the ReadyPrep 2-D clean-up kit (Bio-Rad) to precipitate protein.
The isolated BALF proteins were resuspended in buffer containing 8 M
urea/50 mM NH4HCO3/0.1% ProteaseMax. The protein amount was es-
timated using an RC/DC protein assay from Bio-Rad [31]. Mass spec-
trometry analysis was performed according to a previously optimised
[32].2.3. Label-free analysis
Progenesis label-free LC-MS software version 3.1 from Non-Linear
Dynamics (Newcastle upon Tyne, UK) was used to process the raw
data generated from LC-MS/MS analysis. Data alignment was based on
the LC retention time of each sample, allowing for any drift in retention
time given and adjusted retention time for all runs in the analysis. A ref-
erence run was established with the sample run that yielded most fea-
tures (i.e. peptide ions). The retention times of all of the other runs
were aligned to this reference run and peak intensities were then nor-
malized [33]. A number of criteria were applied to ensure proper iden-
tification of BALF derived proteins, including an ANOVA p-value
between experimental groups of ≤0.05, fold change ≥2 and proteins
with ≥2 peptides matched [34].2.4. ELISA analysis
Human HSP70/HSPA1A DuoSet ELISA; DY1663-05, Human Cystatin
C DuoSet ELISA; DY1196, Human TIMP-1 DuoSet ELISA; DY970-05 &
Human Lipocalin-2/NGAL DuoSet ELISA; DY1757 were used for the ver-
ification study (R&D Systems, Oxon, UK). Each of these ELISA assayswas
performed according to their individual manufacturer's protocol and
guidelines. The concentration of each protein in the serum samples
was measured by comparing the optical density (OD) using a micro-
plate reader (Bio-Tek). Standard curves were calculated for each ELISA
kit.
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The freely available software package PANTHER (http://pantherdb.
org) was used for the bioinformatics analysis of the mass spectrometric
findings generated in this study [35].3. Results
3.1. Proteomic profiling and identification
In total, 267 proteins were found to be statistically significant when
comparing control to AD BALF samples (fold-change ≥2, number of
match peptides ≥2, p-value ≥0.05). Of these 267 significant proteins
(Table 2 – top 30), 39 were found to have a higher abundance in the
control cohort, mainly involved in cellular processes (27.90%), metabol-
ic processes (29.40%) and cellular component organization (22.10%)
(Fig. 1). 228 proteins were of higher abundance in the AD samples
and involved in cellular (24.30%) and metabolic (23.10%) processes.
261 proteins were found to be statistically significant when comparing
control to SqCC BALF samples (fold-change ≥2, number of match pep-
tides ≥2, p-value ≥0.05). Of these 261 significant proteins (Table 3 –
top 30), 62 were found to have a higher abundance in the control co-
hort, with cellular (20.70%) and metabolic (29.30%) processes exten-
sively represented (Fig. 1). 199 proteins were of higher abundance in
the SqCC samples (cellular process, 24.40%; metabolic process,
22.70%). 292 proteins were found to be statistically significant when
comparing AD to SqCC BALF samples (fold-change ≥2, number of
match peptides ≥2, p-value ≥0.05). Of these 292 significant proteins
(Table 4 – top 30), 183 were found to have a higher abundance in the
AD cohort (cellular process, 22.60%; metabolic process, 22.90%) (Fig.
1). 109 proteinswere of higher abundance in the SqCC samples (cellular
process, 30.70%; metabolic process, 25.50%).Table 2
Control v AD proteomics data.
Gene
name
Peptide
count
Confidence
score Anova (p)
Max fold
change
Highest mea
condition
KV402 2 10 1.31E-14 7.7 AD
KV101 3 20 5.22E-12 7.9 AD
KV121 2 9 7.17E-12 6.5 AD
HV302 2 7 2.24E-10 7.6 AD
GNAI1 3 8 3.24E-10 7.3 AD
HV103 3 10 7.06E-10 5.7 AD
CALM 6 42 8.76E-10 9.6 AD
KV110 2 9 6.59E-09 3.6 AD
KV104 3 17 9.96E-09 9.5 AD
KV201 2 10 3.60E-08 11.1 AD
ANXA2 9 41 3.98E-08 3.4 AD
SLPI 10 63 4.95E-08 7.6 AD
PRDX6 4 11 6.76E-08 4.1 AD
S10A2 2 14 7.38E-08 15.5 AD
IGLL5 8 44 8.12E-08 2.5 AD
PSA4 2 6 8.31E-08 8.2 AD
HV320 3 9 8.64E-08 6.2 AD
B2MG 3 17 1.10E-07 7.2 AD
KV302 5 25 1.29E-07 2.1 AD
LDHA 6 24 1.43E-07 3.5 AD
DCD 2 13 1.68E-07 3.6 AD
CD59 3 19 2.24E-07 11.3 AD
DMBT1 20 101 2.36E-07 10.9 AD
KV309 2 9 2.65E-07 3.2 AD
LDHB 8 28 2.70E-07 5.0 AD
ACTN4 9 28 3.11E-07 3.1 AD
KV118 2 10 3.32E-07 10.2 AD
HV303 5 21 4.12E-07 3.6 AD
LV103 2 6 5.63E-07 13.2 AD
ACBP 6 29 6.27E-07 4.9 AD
List of differentially expressed proteins (top 30 hits) when comparing control to AD BALF patie
(XCorr), ANOVA (p-value), fold-change, highest/lowest condition and protein description. See3.2. ELISA data
Four proteins (Cystatin-C, TIMP-1, Lipocalin-2 and HSP70/HSPA1A)
were selected as a representative group from the discovery phase ex-
periments in BALF to verify in patient plasma samples. Commercial
available ELISA kits were available to evaluate the abundance of these
proteins in the verification plasma sample cohort. Cystatin-C, TIMP-1,
Lipocalin-2 and HSP70/HSPA1A passed the following criteria for selec-
tion: p-value ≤0.05, protein fold change N2 and proteins with ≥2 pep-
tides matched. Label-free mass spectrometry analysis of BALF samples
found that Cystatin-C was elevated in AD compared to SqCC (4.8-fold;
p-value = 4.89E-08) and elevated in SqCC compared to control (4.5-
fold; p-value = 0.01) (Tables – supplemental). TIMP-1 was discovered
to be elevated in AD compared to SqCC (2.2-fold; p-value= 0.0001), el-
evated in SqCC compared to control (2.2-fold; p-value = 0.02) and ele-
vated in AD compared to control (2-fold; p-value= 2.39E-05) (Tables –
supplemental). Lipocalin-2 was found to have an increased abundance
in SqCC compared to control (2.2-fold; p-value = 0.006) (Tables – sup-
plemental). HSP70/HSPA1A was increased in AD compared to SqCC
(2.2-fold; p-value = 0.001) and in control compared to SqCC (2.1-
fold; p-value = 0.002) (Tables – supplemental).
Verification of these four proteins (Cystatin-C, TIMP-1, Lipocalin-2
and HSP70/HSPA1A)was performed in plasma samples using sandwich
ELISAs to measure natural and recombinant protein levels. The mean
concentration for Cystatin-C was 716 ng/ml, 8027 ng/ml and
6981 ng/ml in control, AD and SqCC respectively with associated
Kruskal-Wallis one-way ANOVA p-values of 1.53E-07, 7.13E-06 and
0.0002 (Fig. 2). TIMP-1 was discovered to have mean concentration
values of 2004 ng/ml, 3927 ng/ml and 8280 ng/ml in control, AD and
SqCC respectively with associated p-values of 2.20E-06, 3.81E-07 and
4.86E-06 (Fig. 2). Mean concentration values for Lipocalin-2 were
found to be 980 ng/ml, 1404 ng/ml and 1537 ng/ml in control, AD and
SqCC respectively with associated p-values of 0.02, 0.03 and 0.1 (Fig.n Lowest mean
condition Description
Control Ig kappa chain V-IV region Len
Control Ig kappa chain V-I region AG
Control Ig kappa chain V-I region Ni
Control Ig heavy chain V-III region WEA
Control Guanine nucleotide-binding protein G(i) subunit alpha-1
Control Ig heavy chain V-I region V35
Control Calmodulin
Control Ig kappa chain V-I region HK102 (Fragment)
Control Ig kappa chain V-I region CAR
Control Ig kappa chain V-II region Cum
Control Annexin A2
Control Antileukoproteinase
Control Peroxiredoxin-6
Control Protein S100-A2
Control Immunoglobulin lambda-like polypeptide 5
Control Proteasome subunit alpha type-4
Control Ig heavy chain V-III region GAL
Control Beta-2-microglobulin
Control Ig kappa chain V-III region SIE
Control L-lactate dehydrogenase A chain
Control Dermcidin
Control CD59 glycoprotein
Control Deleted in malignant brain tumors 1 protein
Control Ig kappa chain V-III region VG (Fragment)
Control L-lactate dehydrogenase B chain
Control Alpha-actinin-4
Control Ig kappa chain V-I region WEA
Control Ig heavy chain V-III region VH26
Control Ig lambda chain V-I region NEW
Control Acyl-CoA-binding protein
nt samples. The table includes information on gene name, peptide count, confidence score
supplemental tables for full list of significant proteins.
Fig. 1. Biological process analysis. Biological process analysis (Panther) for (A) control v AD, (B) control v SqCC and (C) AD v SqCC.
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isons (control v AD; control v SqCC or AD v SqCC)withmean concentra-
tion values of 5.4 ng/ml, 4.3 ng/ml and 11.2 ng/ml in control, AD and
SqCC respectively (Fig. 2).
4. Discussion
Blood is an accessible, acceptable, andwidely used biological sample
for identification of biomarkers of disease [36]. However, one of the
greatest challenges in proteomic analysis of both serum and plasma
samples is the wide range of concentration of different proteins [37].The dynamic range of proteins in blood limits the ability to examine
the blood proteome for discovery due to the presence of a few proteins
at very high concentrations [38,39].
Arising from the inherent analytical challenges related to blood pro-
teomics, proximal fluids have gained increasing attention for
conducting candidate protein biomarker discovery [40]. Compared to
distal biofluids (e.g. blood), proximal biofluids are less complex and
are likely to be significantly enriched in potential biomarker candidates
due to their vicinity to the site of disease [29,41]. Once a candidate bio-
marker is discovered in a proximal biofluid, targeted verification and
validation can then be performed in blood.
Table 3
Control v SqCC proteomics data
Gene name Peptide count Confidence score Anova (p) Max fold change Highest mean condition Lowest mean condition Description
A1AG2 4 35 1.96E-12 8.2 SqCC Control Alpha-1-acid glycoprotein 2
A1AT 31 273 3.45E-08 4.0 SqCC Control Alpha-1-antitrypsin
KV101 3 18 1.16E-07 6.0 SqCC Control Ig kappa chain V-I region AG
IGHG1 11 124 1.30E-07 4.7 SqCC Control Ig gamma-1 chain C region
KV302 2 14 5.33E-07 2.5 SqCC Control Ig kappa chain V-III region SIE
A2GL 4 39 5.47E-07 4.8 SqCC Control Leucine-rich alpha-2-glycoprotein
FIBA 5 21 7.91E-07 4.8 SqCC Control Fibrinogen alpha chain
KNG1 4 15 1.00E-06 4.2 SqCC Control Kininogen-1
CBG 4 12 1.02E-06 2.9 SqCC Control Corticosteroid-binding globulin
K2C5 8 39 1.50E-06 4.0 SqCC Control Keratin, type II cytoskeletal 5
C1S 2 7 2.06E-06 7.7 SqCC Control Complement C1s subcomponent
PNPH 3 9 2.31E-06 3.6 SqCC Control Purine nucleoside phosphorylase
HPTR 8 38 2.56E-06 8.7 SqCC Control Haptoglobin-related protein
MYH9 12 53 3.10E-06 5.0 SqCC Control Myosin-9
NUCB1 2 5 5.04E-06 4.4 Control SqCC Nucleobindin-1
KV401 2 6 5.39E-06 3.0 SqCC Control Ig kappa chain V-IV region (Fragment)
PSB10 2 10 7.40E-06 3.5 SqCC Control Proteasome subunit beta type-10
S10A2 2 7 7.44E-06 32.9 SqCC Control Protein S100-A2
IGKC 10 72 7.67E-06 2.3 SqCC Control Ig kappa chain C region
ACBP 2 7 9.17E-06 4.5 SqCC Control Acyl-CoA-binding protein
H4 6 17 9.43E-06 3.6 SqCC Control Histone H4
CFAH 12 64 1.01E-05 4.0 SqCC Control Complement factor H
K1C13 13 81 1.05E-05 31.2 SqCC Control Keratin, type I cytoskeletal 13
APOH 9 45 1.54E-05 3.4 SqCC Control Beta-2-glycoprotein 1
LDHA 7 31 1.62E-05 4.3 SqCC Control L-lactate dehydrogenase A chain
IGHM 7 38 1.87E-05 3.5 SqCC Control Ig mu chain C region
K2C8 5 21 1.92E-05 2.2 Control SqCC Keratin, type II cytoskeletal 8
TGM3 8 53 1.98E-05 8.4 SqCC Control
Protein-glutamine gamma-
glutamyltransferase E
ALBU 59 464 2.03E-05 4.5 SqCC Control Serum albumin
ANT3 8 40 2.23E-05 2.8 SqCC Control Antithrombin-III
List of differentially expressed proteins (top 30 hits)when comparing control to SqCC BALF patient samples. The table includes information on gene name, peptide count, confidence score
(XCorr), ANOVA (p-value), fold-change, highest/lowest condition and protein description. See supplemental tables for full list of significant proteins.
Table 4
AD v SqCC proteomics data.
Gene
name
Peptide
count
Confidence
score Anova (p)
Max fold
change
Highest mean
condition
Lowest mean
condition Description
CYTC 4 22 4.89E-08 4.9 AD SqCC Cystatin-C
ZA2G 19 111 1.58E-07 4.2 AD SqCC Zinc-alpha-2-glycoprotein
TBB1 4 15 1.80E-07 6.2 AD SqCC Tubulin beta-1 chain
CATC 5 24 9.74E-07 3.3 AD SqCC Dipeptidyl peptidase 1
NHRF1 4 17 1.35E-06 3.6 AD SqCC Na(+)/H(+) exchange regulatory cofactor NHE-RF1
MDHC 4 13 3.96E-06 3.7 AD SqCC Malate dehydrogenase, cytoplasmic
K2C5 8 34 4.58E-06 4.5 SqCC AD Keratin, type II cytoskeletal 5
S10A8 5 29 6.35E-06 3.9 SqCC AD Protein S100-A8
CRIP1 3 17 7.03E-06 7.0 AD SqCC Cysteine-rich protein 1
ABHEB 2 6 7.28E-06 3.9 AD SqCC Alpha/beta hydrolase domain-containing protein 14B
CD59 3 19 9.49E-06 6.7 AD SqCC CD59 glycoprotein
CASPE 4 12 1.08E-05 4.6 SqCC AD Caspase-14
CLIC1 3 13 1.24E-05 5.0 AD SqCC Chloride intracellular channel protein 1
H90B2 2 10 1.46E-05 4.0 AD SqCC Putative heat shock protein HSP 90-beta 2
TRFE 45 295 1.48E-05 3.0 SqCC AD Serotransferrin
HNRPD 2 9 1.64E-05 3.0 AD SqCC Heterogeneous nuclear ribonucleoprotein D0
NUCL 4 16 1.93E-05 2.2 AD SqCC Nucleolin
ELNE 6 41 2.31E-05 11.8 SqCC AD Neutrophil elastase
KV118 2 7 2.60E-05 7.1 AD SqCC Ig kappa chain V-I region WEA
TTHY 9 75 3.13E-05 4.8 AD SqCC Transthyretin
MYG 2 7 4.59E-05 7.7 AD SqCC Myoglobin
APOH 3 12 5.12E-05 3.6 SqCC AD Beta-2-glycoprotein 1
PARK7 3 19 5.42E-05 4.6 AD SqCC Protein DJ-1
KLK11 4 17 6.09E-05 3.5 AD SqCC Kallikrein-11
HSP72 5 18 7.06E-05 3.1 AD SqCC Heat shock-related 70 kDa protein 2
PEBP1 7 35 7.48E-05 3.2 AD SqCC Phosphatidylethanolamine-binding protein 1
A1AG2 4 33 7.56E-05 3.1 SqCC AD Alpha-1-acid glycoprotein 2
HGB1A 2 11 7.65E-05 3.1 AD SqCC Putative high mobility group protein B1-like 1
CAP7 4 33 7.66E-05 5.8 SqCC AD Azurocidin
NUCB2 6 27 7.76E-05 3.4 AD SqCC Nucleobindin-2
List of differentially expressed proteins (top 30 hits) when comparing AD to SqCC BALF patient samples. The table includes information on gene name, peptide count, confidence score
(XCorr), ANOVA (p-value), fold-change, highest/lowest condition and protein description. See supplemental tables for full list of significant proteins.
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Fig. 2. ELISA verification. Box-and-Whisker plots (A) HSP70, (B) Cystatin-C, (C) Lipocalin-2 and (D) TIMP-1 levels in control, AD and SqCC plasma samples. Box-and-Whisker plots
represent data with boxes ranging from the 25th to the 75th percentile of the observed distribution of values. The bold line of the box displays the median value for plasma levels of
HSP70, Cystatin-C, Lipocalin-2 and TIMP-1. Whiskers span minimum to maximum observed values. Statistical significance was tested by Kruskal-Wallis one-way ANOVA using SPSS
15.0 for Windows software. (*p ≤ 0.05: significant; **p ≤ 0.01: very significant).
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soluble components such as phospholipids, nucleic acids, peptides and
proteins [42]. The utility of BALF has been exploited for many years in
clinical research, with recent technological advances permitting de-
tailed proteomic profiling of the protein/peptide signature in particular
lung diseases. This approach provides a rich source of candidate bio-
markers, in addition to providing insight into the complex pathological
mediators associated with lung diseases at the molecular level [43,44].
The data presented in this study demonstrates a marked increase in
the abundance of proteins involved in cellular and metabolic processes
in patients with lung cancer compared to controls. In agreement with
ourfindings, Almatroodi et al. published a list of proteins found to be in-
creased in BALF from primary lung adenocarcinoma compared to con-
trols using liquid chromatography-mass spectrometry [45]. Of the 33
proteins consistently overexpressed in lung adenocarcinoma samples
compared to controls presented in that study, ACTN4, ANXA2, CLIC1,
GRP78, H4, LKHA4, S10A8, SAMH1 were also found to be of greater
abundance in AD compared to control groups in this study.
Following selection of four candidate proteins for verification in
plasma, TIMP-1, Lipocalin-2 and Cystatin-C were all found to be signifi-
cantly elevated in NSCLC compared to control. This indicates that there
is a good level of agreement between proteins found to have different
abundance levels in BALF (cancer v control) and plasma samples (can-
cer v control), furthermore the increase was a consistent finding irre-
spective of cancer subtype, i.e. AD or SqCC.
`TIMP-1 was discovered to be elevated in SqCC compared to con-
trol and AD compared to control when analysing BALF samples by
mass spectrometry. Verification of these results in plasma samples
found that TIMP-1 had significantly higher levels in AD and SqCC
compared to the control group as measured by ELISA. TIMPs are nat-
ural inhibitors of matrix metalloproteinases (MMPs) present in most
tissues and body fluids [46]. By inhibiting MMPs activities, they par-
ticipate in tissue remodelling of the extracellular matrix. The balance
between MMPs and TIMPs activities is involved in both normal and
pathological processes such as wound healing, tissue remodelling,
angiogenesis, tumour development and metastasis [47], [48]. In can-
cer, MMP over-expression is thought to play an important role in tu-
mour invasion and metastasis. The major function of TIMP-1 is as aninhibitor of MMPs, but several independent roles in tumour develop-
ment are likely [49], [50].
Neutrophil gelatinase-associated lipocalin (NGAL), also known as
Lipocalin-2, is a 178-amino acid protein which exists in threemolecular
forms, a 25-kDamonomer, a 45-kDa homodimer, and a 135-kDa hetero-
dimer. A number of malignant tumours consistently overexpressed
NGAL with increased concentration in blood, urine, and other biologic
fluids [51]. In this study, BALF levels of Lipocalin-2 were increased in
SqCC compared to control with mean concentration values significantly
elevated in AD and SqCC compared to control during verification analy-
sis of plasma samples. NGAL is also commonly associated with tumour
size, stage, and invasiveness [52]. Ricci et al. found that there was an as-
sociation between NGAL serum levels and bladder cancer stage. The au-
thor suggests that serumNGALmay be a useful non-invasive biomarker
to provide clinical information for bladder cancer disease management
[53]. Studies investigating the role of NGAL in lung cancer have discov-
ered high levels of NGAL associated with lung adenocarcinoma at both
the protein and mRNA level [54], [55].
Cystatin C is a small 13 kDa protein that is a member of the cysteine
proteinase inhibitor family. Cystatin-C was elevated in SqCC compared
to control during discovery phase analysis of BALF, this was confirmed
by ELISA in plasma as it was significantly elevated in AD and SqCC com-
pared to control. Cystatin-C is likely to be biologically relevant as an im-
balance between cysteine proteases and their inhibitors arises in
malignancy, influencing tumour cell invasion and metastasis [56]. Mi-
croarray analysis has revealed that cystatin Cwas one of themost highly
upregulated genes in multiple myeloma [57]. Additionally, Kos et al.
demonstrated that a significant correlation between increased serum
cystatin C and malignant progression in melanoma and colorectal can-
cer exists [58].
While the main focus of this investigation was to identify proteins
with different abundance levels in BALF and verify these results in plas-
ma samples, a significant number of proteins were found to be changed
in BALF samples when comparing AD to SqCC. A finding of particular
interest was that folate receptor alpha was increased 14-fold in AD
compared to SqCC. Previous work has shown that folate receptor
alpha expression had a high discriminatory capacity for lung adenocar-
cinomas versus squamous cell carcinomas as determined by
103A. Hmmier et al. / BBA Clinical 7 (2017) 97–104immunohistochemistry [59,60]. The utility of MS-based quantitative
proteomics as an additional piece of information to facilitate clinicians
in the classifications of tumours is a significant area in development,
as more treatments are specifically aimed at squamous and non-squa-
mous cell carcinoma. Also, a better understanding of the NSCLC histo-
logical subtypes may provide valuable insight in support of developing
targeted therapeutics that are specific for precisely classified lung tu-
mours. Several new targeted therapies have been recently approved
for non-squamous NSCLC that inhibit Vascular Endothelial Growth Fac-
tor (VEGF), Epidermal Growth Factor Receptor (EGFR), Anaplastic Lym-
phoma Kinase (ALK), and Reactive Oxygen Species (ROS-1) [61]. As
more driver mutations are discovered and therapeutic compounds de-
veloped to target these abnormal pathways, precise diagnosis of lung
cancer and its subtypes will be crucial [62]. Protein expression and sig-
nalling in either BALF or plasma may have clinical relevance in the fu-
ture through its ability to precisely differentiate subtypes and facilitate
lung cancer diagnosis.
The variety of patients treated in the clinic, tumour heterogeneity and
treatment-related factors will significantly influence the protein constitu-
ents of BALF. This is an important limitation in the identification of accu-
rate biomarker profiles, and necessitates the development of biomarker
panels and stratification of patients based on previous medical history
in order to facilitate themost accurate results based on themeasurement
of protein levels. Proteins are dynamic and constantly turned over in cells,
characteristics thatmake themvery sensitive to factors such as disease se-
verity and previous/current medication history. A single BALF-based bio-
marker is unlikely to have sufficient sensitivity or specificity for use as a
stand-alone test, therefore a panel of unrelated biomarkers may be
more effective.When ambiguous results are encountered frombiomarker
panel testing it may indicate technical difficulties with measuring multi-
ple biomolecules. It is also likely that some complex diseases are not ame-
nable to monitoring with biomarkers and therefore other approaches
such as scanning-based procedures may be more suitable.
The BALF proteome is a very complex mixture with many of the top
protein hits by mass spectrometry found to be well-established blood-
based proteins, namely albumin, haptoglobin and immunoglobin pro-
teins. However, when compared to un-fractioned plasma/serum digests,
BALF does contain more low abundant protein identifications and there-
foremay facilitate the analysis ofmore cellular secreted/shed proteins as-
sociated with disease. Watson and co-workers presented data showing
the differences in the proteolyticfingerprints of serumandBALF in guinea
pigs [63]. This is very important in the context of protein degradation and
subsequentmeasurement of candidate biomarkers in serum compared to
BALF and the interpretation of data from these two pools of bodily fluids.
In conclusion, the findings of this study indicate that the BALF prote-
ome is significantly altered in NCSLC samples compared to control. In ad-
dition, significant differences in the protein profile between AD and SqCC
in BALF could also be used to help distinguish lung cancer sub-types in
this population. The elevation of specific proteins in patients diagnosed
with AD and SqCCmay be used to develop a specific biomarker panel as-
sociated with each NSCLC sub-type. Certain candidate proteins, particu-
larly Cystatin-C, TIMP-1 and Lipocalin, had altered abundance levels in
BALF and correlated well with increased abundance in plasma. Proteins
expressed at different levels in BALF or plasma may also provide insight
into the molecular mechanisms associated with malignancy, particularly
in relation to metabolism, cellular processing, and the immune response.
Overall the findings of this study support the use of BALF as a robust
proximal biofluid for the discovery of candidate biomarkers in lung can-
cer. Our results demonstrate that BALF proteomic profiles are transfer-
rable into blood, which is a promising finding in the search for non-
invasive biomarkers to diagnose and monitor lung cancer.
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